Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 13 September 2017, 13:25 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak
The Answer to Viruses and Bacteria in the Home! Eliminates Viruses & Bacteria, Antimicrobial Action that Lasts for 1 Week

TOKYO, Sept 13, 2017 - (JCN Newswire) - Eisai Co., Ltd. will launch Etak Antimicrobial Spray Alpha (classified as miscellaneous goods), which contains long-acting antimicrobial agent Etak, on September 19 (Tuesday). This product eliminates viruses and bacteria with an antimicrobial action that lasts for one week.

Etak, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component in Etak chemically binds the antimicrobial component to the spray area, providing an antimicrobial effect that lasts for one week.

In the home, there are many surfaces and items, such as doorknobs, bannisters, tables, flooring, and toys, to which viruses and bacteria can spread easily when touched. This product is an answer to the needs of consumers who wish to keep those viruses and bacteria at bay. We suggest habitually using Etak Antimicrobial Spray Alpha to eliminate viruses and bacteria in the home. Additionally, this product contains no alcohol and is both scentless and colorless, making it ideal for use on a wide variety of surfaces and items in the home.

Eisai is also marketing Etak Antimicrobial Spray, an alcohol type spray for mouth masks which uses the same long-acting antimicrobial agent Etak. By spraying it on a mouth mask prior to use, you can prevent viruses and bacteria from collecting on the mask for 24 hours.

Eisai remains committed to ensuring the delivery of products that satisfy the diversified needs of consumers and to making further contributions to increase the benefits provided to them.

Product Outline

1. Product Name: Etak Antimicrobial Spray Alpha (Miscellaneous Goods)

2. Ingredients: Water, long-acting antimicrobial agent (compound containing ethoxysilane), solubilizing agent, stabilizing agent

3. Directions for use:
- Please remove stopper when using. Returning the stopper locks the product.
- Please keep the nozzle 20-30cm away from the target and spray an appropriate amount.
- When using for the first time, please press the spray button a few times to activate the spray mechanism.
- In order to achieve a uniform spread, please wipe the surface with a cloth or other item after spraying.
- Please do not use this product upside down.

4. Volume / Suggested retail price (excluding tax): 250ml / 1,280 yen

5. Manufacturer: Jex Co., Ltd.

6. Supplier: Eisai Co., Ltd.

http://www.acnnewswire.com/topimg/Low_EisaiEtak.jpg
Product Photograph

About long-acting antimicrobial agent Etak

Etak was developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented longacting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as adhesive. When a quaternary ammonium salt is sprayed onto an object, it would normally lose its antimicrobial properties upon drying. However, with Etak, the adhesive component chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Sept 13, 2017 13:25 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Multimedia
Etak Antimicrobial Spray Alpha
View Image
 

Eisai
June 14, 2018 09:11 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
June 13, 2018 11:53 HKT/SGT
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA
June 11, 2018 11:44 HKT/SGT
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA
June 6, 2018 11:16 HKT/SGT
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
June 5, 2018 09:08 HKT/SGT
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
June 4, 2018 20:10 HKT/SGT
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting
May 31, 2018 12:33 HKT/SGT
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma
May 28, 2018 16:06 HKT/SGT
Eisai: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" will be Presented at DDW2018
May 25, 2018 14:00 HKT/SGT
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease
May 25, 2018 10:43 HKT/SGT
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: